Results 11 to 20 of about 7,499 (195)

Brimonidine Therapy for Protection From Noise-Induced Hearing Loss. [PDF]

Aging Cell
In this study, we demonstrate that brimonidine protects against noise‐induced hearing loss in young mice by suppressing glutamate synthesis and vesicle transport, thereby reducing excitotoxicity and preserving synaptic integrity. Such early intervention may prevent age‐related hearing loss, highlighting brimonidine's potential as a therapeutic agent ...
Cai J, Zhang N, Song Y, Chen C, Kong L, Ai Y, Jin Y, Gao Q, Zhang D, Xu L, Wang H.   +10 more
europepmc   +2 more sources

Multidisciplinary Consideration of Potential Pathophysiologic Mechanisms of Paradoxical Erythema with Topical Brimonidine Therapy. [PDF]

, 2016
Rosacea is a chronic inflammatory disease with transient and non-transient redness as key characteristics. Brimonidine is a selective α2-adrenergic receptor (AR) agonist approved for persistent facial erythema of rosacea based on significant efficacy and
Detmar, Michael, Di Nardo, Anna, Docherty, James R, Holmes, Anna, Lorton, Dianne, Schäfer, Gregor, Steinhoff, Martin   +6 more
core   +2 more sources

Therapeutic approaches with intravitreal injections in geographic atrophy secondary to age-related macular degeneration: current drugs and potential molecules [PDF]

, 2019
The present review focuses on recent clinical trials that analyze the efficacy of intravitreal therapeutic agents for the treatment of dry age-related macular degeneration (AMD), such as neuroprotective drugs, and complement inhibitors, also called ...
Cerini, Alberto, Greco A., La Cava M, Lambiase A, Limoli PG, Nebbioso M   +5 more
core   +1 more source

Rare diseases leading to childhood Glaucoma. epidemiology, pathophysiogenesis, and management [PDF]

, 2015
Noteworthy heterogeneity exists in the rare diseases associated with childhood glaucoma. Primary congenital glaucoma is mostly sporadic; however, 10% to 40% of cases are familial. CYP1B1 gene mutations seem to account for 87% of familial cases and 27% of
Abdolrahimzadeh, Solmaz, CONTESTABILE, Maria Teresa, FAMELI, VALERIA, Mollo, Roberto, Perdicchi, Andrea, RECUPERO, Santi Maria   +5 more
core   +3 more sources

Use of an alternative method to evaluate erythema severity in a clinical trial: difference in vehicle response with evaluation of baseline and postdose photographs for effect of oxymetazoline cream 1·0% for persistent erythema of rosacea in a phase IV study. [PDF]

, 2019
BackgroundOnce-daily topical oxymetazoline cream 1·0% significantly reduced persistent facial erythema of rosacea in trials requiring live, static patient assessments.ObjectivesTo evaluate critically the methodology of clinical trials that require live ...
Alvandi, N, Baldwin, HE, Del Rosso, JQ, Eichenfield, LF, Harper, J, Hebert, AA, Kaoukhov, A, Kircik, LH, Stein-Gold, L, Tan, JKL, Webster, GF   +10 more
core   +1 more source

Ocular and Systemic Pharmacokinetics of Brimonidine and Timolol After Topical Administration in Rabbits: Comparison Between Fixed-Combination and Single Drugs

Ophthalmology and Therapy, 2020
Introduction This study was aimed to compare ocular tissue distribution and systemic exposure of brimonidine and timolol after single topical administration to rabbits of fixed-combination ophthalmic solution of 0.1% brimonidine tartrate and 0.5% timolol
Gen Suzuki, Eriko Kunikane, Keisuke Shinno, Seiko Kozai, Masaaki Kurata, Akio Kawamura   +5 more
doaj   +1 more source

Cationic supramolecular hydrogels for overcoming the skin barrier in drug delivery [PDF]

, 2018
A cationic bis‐imidazolium‐based amphiphile was used to form thermoreversible nanostructured supramolecular hydrogels incorporating neutral and cationic drugs for the topical treatment of rosacea.
Amabilino, David B., Calpena Campmany, Ana Cristina, González Campo, Arántzazu, Jiménez Newman, Claire, Limón Magaña, David, Pérez García, M. Lluïsa (Maria Lluïsa), Rodrigues, Ana Mafalda Nunes   +6 more
core   +1 more source

Changes in visual function after intraocular pressure reduction using antiglaucoma medications [PDF]

, 2009
Purpose To evaluate the change in visual function after starting glaucoma treatment and correlate this to a decrease in intraocular pressure (IOP) in primary open-angle glaucoma patients.Methods A prospective, randomized clinical trial was carried out ...
A Harris, A Heijl, AS Hawkins, C Holmin, CS Tsai, D Regan, DW Evans, DW Evans, GN Pomerance, HA Quigley, J Flammer, JE Ross, JS Pointer, L A S Melo, LJ Katz, M V Piassi, O Arend, RN Weinreb, S Salim, SA Gandolfi, SA Gandolfi, T S Prata, WC Stewart   +22 more
core   +2 more sources

24-h Efficacy of Glaucoma Treatment Options [PDF]

, 2016
Current management of glaucoma entails the medical, laser, or surgical reduction of intraocular pressure (IOP) to a predetermined level of target IOP, which is commensurate with either stability or delayed progression of visual loss.
Banu, Bozkurt., Garcia-Feijoo, Julian, Katsanos, Andreas, Konstas, Anastasios, Miglior, Stefano, Pfeiffer, Norbert, Quaranta, Luciano, Rossetti, Luca, Shaarawy, Tarek   +8 more
core   +2 more sources

Neuroprotective properties of Brimonidine

Офтальмохирургия, 2019
Purpose. To summarize relevant data from publications appearing in the peer-reviewed scientific literature since1991 about mechanisms of neurodegeneration in glaucoma and the possibilities of neuroprotection; in particular, analysis of the results of ...
Т. N. Mikhailova
doaj   +1 more source